-
Brentuximab vedotin, sold
under the
brand name Adcetris, is an antibody-drug
conjugate medication used to
treat relapsed or
refractory Hodgkin lymphoma...
-
Enfortumab vedotin, sold
under the
brand name Padcev, is an antibody-drug
conjugate used for the
treatment of
urothelial cancer. It is a nectin-4-directed...
-
Tisotumab vedotin, sold
under the
brand name Tivdak, is an antibody-drug
conjugate used to
treat cervical cancer. It is a
combination of tisotumab, a...
-
Polatuzumab vedotin, sold
under the
brand name Polivy, is a CD79b-directed antibody-drug
conjugate medication used for the
treatment of
diffuse large...
-
tisotumab vedotin Examples:
Sofituzumab vedotin Polatuzumab vedotin (RG7596)
Enfortumab vedotin Pinatuzumab vedotin Lifastuzumab vedotin Brentuximab vedotin Glembatumumab...
-
antitumor activity. The company's
flagship product Adcetris (brentuximab
vedotin) is
commercially available for four
indications in more than 65 countries...
-
Disitamab vedotin (trade name Aidixi) is a drug for the
treatment of
various types of
solid tumors. It is an antibody-drug
conjugate that
consists of...
-
Telisotuzumab vedotin is a
monoclonal antibody developed by
AbbVie for non-small cell lung cancer. Camidge, D. Ross; Barlesi, Fabrice; Goldman, Jonathan...
-
Glembatumumab vedotin (also
known as CDX-011 and CR011-vcMMAE) is an antibody-drug
conjugate (ADC) that
targets cancer cells expressing transmembrane...
-
Lifastuzumab vedotin (INN;
development code DNIB0600A) is an
experimental monoclonal antibody-drug
conjugate designed for the
treatment of cancer. This...
